Compare SKM & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKM | CRL |
|---|---|---|
| Founded | 1984 | 1947 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.8B |
| IPO Year | 1999 | 1999 |
| Metric | SKM | CRL |
|---|---|---|
| Price | $34.88 | $260.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $198.27 |
| AVG Volume (30 Days) | ★ 2.4M | 786.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | $4.41 | N/A |
| Revenue Next Year | $1.85 | $3.04 |
| P/E Ratio | $31.64 | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $19.66 | $144.26 |
| 52 Week High | $47.18 | $242.73 |
| Indicator | SKM | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 72.25 |
| Support Level | $29.27 | $153.47 |
| Resistance Level | $36.89 | N/A |
| Average True Range (ATR) | 1.13 | 8.53 |
| MACD | 0.38 | 0.51 |
| Stochastic Oscillator | 75.41 | 77.93 |
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production, as well as developing e-commerce and internet platform businesses, these were all spun off into the separate SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.